Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Current Deferred Tax Assets (2018 - 2020)

Historic Current Deferred Tax Assets for Ernexa Therapeutics (ERNA) over the last 3 years, with Q4 2020 value amounting to $72000.0.

  • Ernexa Therapeutics' Current Deferred Tax Assets fell 7372.26% to $72000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $72000.0, marking a year-over-year decrease of 7372.26%. This contributed to the annual value of $72000.0 for FY2020, which is 7372.26% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Current Deferred Tax Assets of $72000.0 as of Q4 2020, which was down 7372.26% from $274000.0 recorded in Q4 2019.
  • Ernexa Therapeutics' Current Deferred Tax Assets' 5-year high stood at $424000.0 during Q4 2018, with a 5-year trough of $72000.0 in Q4 2020.
  • In the last 3 years, Ernexa Therapeutics' Current Deferred Tax Assets had a median value of $274000.0 in 2019 and averaged $256666.7.
  • In the last 5 years, Ernexa Therapeutics' Current Deferred Tax Assets crashed by 3537.74% in 2019 and then crashed by 7372.26% in 2020.
  • Quarter analysis of 3 years shows Ernexa Therapeutics' Current Deferred Tax Assets stood at $424000.0 in 2018, then plummeted by 35.38% to $274000.0 in 2019, then tumbled by 73.72% to $72000.0 in 2020.
  • Its Current Deferred Tax Assets was $72000.0 in Q4 2020, compared to $274000.0 in Q4 2019 and $424000.0 in Q4 2018.